Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Marvell: 115 Milliarden Dollar Deal mit Lumentum – Aktie zieht an (Der Aktionaer) +++ LUMENTUM Aktie -4,33%

IDEXX Aktie

 >IDEXX Aktienkurs 
515 EUR    +4.7%    (TradegateBSX)
Ask: 525 EUR / 12 Stück
Bid: 515 EUR / 12 Stück
Tagesumsatz: 51 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IDEXX Aktie über LYNX handeln
>IDEXX Performance
1 Woche: -2,4%
1 Monat: +5,6%
3 Monate: +1,4%
6 Monate: +3,6%
1 Jahr: -8,2%
laufendes Jahr: -16,2%
>IDEXX Aktie
Name:  IDEXX LABS INC. DL-,10
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45168D1046 / 888210
Symbol/ Ticker:  IX1 (Frankfurt) / IDXX (NASDAQ)
Kürzel:  FRA:IX1, ETR:IX1, IX1:GR, NASDAQ:IDXX
Index:  S&P500, Nasdaq100
Profil:  IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits,..
>Volltext..
Marktkapitalisierung:  38909.84 Mio. EUR
Unternehmenswert:  39698.26 Mio. EUR
Umsatz:  4079.8 Mio. EUR
EBITDA:  1448.55 Mio. EUR
Nettogewinn:  1021.16 Mio. EUR
Gewinn je Aktie:  12.83 EUR
Schulden:  982.12 Mio. EUR
Liquide Mittel:  176.46 Mio. EUR
Operativer Cashflow:  1225.56 Mio. EUR
Bargeldquote:  0.15
Umsatzwachstum:  16.32%
Gewinnwachstum:  19.26%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IDEXX
Letzte Datenerhebung:  02.11.26
>IDEXX Kennzahlen
Aktien/ Unternehmen:
Aktien: 78.78 Mio. St.
Frei handelbar: 99.62%
Rückkaufquote: 2.43%
Mitarbeiter: 11000
Umsatz/Mitarb.: 0.35 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 24.8%
Bewertung:
KGV: 41.63
KGV lG: 39.28
KUV: 10.03
KBV: 28.97
PEG-Ratio: 2.2
EV/EBITDA: 27.41
Rentabilität:
Bruttomarge: 62.53%
Gewinnmarge: 25.03%
Operative Marge: 32.12%
Managementeffizenz:
Gesamtkaprendite: 33.65%
Eigenkaprendite: 74.21%
>IDEXX Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Tiermedizin/ Tierbehandlung
 
02.11.26 - 13:12
ROUNDUP: IDEXX Laboratories Boost FY26 Outlook (AFX)
 
WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) raised its earnings and revenue guidance for the f......
02.11.26 - 13:01
IDEXX Laboratories Inc Q3 Profit Climbs (AFX)
 
WASHINGTON (dpa-AFX) - IDEXX Laboratories Inc (IDXX) released earnings for its third quarter that Increases, from last yearThe company's earnings totaled $317.145 million, or $4.01 per share. This......
02.11.26 - 12:57
IDEXX Labs beats estimates, raises guidance as stock gains (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 12:39
IDEXX Laboratories beats top-line and bottom-line estimates; updates FY26 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 12:36
IDEXX Laboratories Announces Third Quarter Results (Business Wire)
 
Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic. Double-digit organic revenue growth was led by strong volume expansion, including benefits from IDEXX's innovations and excellent commercial execution. Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving installed base to nearly 11,000 instruments. Delivers EPS of $4.01, an increase of 18% as reported and 22% on a comparable basis, with operating margin up 100 basis points as reported and 60 basis points on a comparable basis. Increases 2026 revenue guidance to $4,741 million - $4,767 million, up $32 million at midpoint, reflecting strong CAG Diagnostics recurring revenue performance. Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of...
30.10.26 - 16:48
IDEXX Laboratories Q3 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.10.26 - 16:30
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
 
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
23.10.26 - 16:00
Here′s How IDEXX Laboratories Is Placed Ahead of Q3 Earnings (Zacks)
 
IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains....
20.10.26 - 19:45
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
 
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
20.10.26 - 14:51
Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.10.26 - 14:48
Jefferies stuft Zoetis und Elanco wegen Preissetzungsrisiken ab – IDEXX bleibt Favorit (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
19.10.26 - 19:45
Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
 
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
15.10.26 - 15:24
IDEXX Laboratories' Q3 2026 Earnings: What to Expect (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
01.10.26 - 17:36
IDEXX Laboratories to Release 2026 Third Quarter Financial Results (Business Wire)
 
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 715328. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolv...
17.09.26 - 16:45
IDEXX Stock Gains Following the Acquisition of CoVet (Zacks)
 
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance....
16.09.26 - 14:18
IDEXX Buys CoVetAI To Expand Veterinary Workflow Intelligence (AFX)
 
WASHINGTON (dpa-AFX) - Veterinary diagnostics company IDEXX Laboratories, Inc. (IDXX) announced on Wednesday that it has acquired CoVetAI Inc., a provider of AI-native ambient listening and clinic......
16.09.26 - 13:33
IDEXX Laboratories buys CoVetAI (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.09.26 - 13:06
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence (Business Wire)
 
Acquisition strengthens IDEXX's connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilizationWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians' time. The acquisition expands the value of IDEXX's software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated int...
14.09.26 - 18:01
IDEXX auf Morgan Stanley Konferenz: Wachstumsplan setzt auf Innovation (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.09.26 - 17:42
IDEXX auf der Barclays Konferenz: Diagnostik treibt Wachstum trotz rückläufiger Tierarztbesuche (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Unkraut ist alles, was nach dem Jäten wieder wächst. - Mark Twain
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!